Upregulated in tumor tissues, increases VEGF expression as a result of elevated nitric oxide levels and correlates with tumor growth and angiogenesis in vivo. Targeting of DDAH1 with a therapeutic compound resulted in regression of tumor size and tumor vasculature density. Here, DDAH1 is linked to neoplasm.